Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock
Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
Selection of tigecycline in severe sepsis and septic shock patients in empirical antibiotic
therapy (Hai Zheng Energy Star ®) combined with piperacillin / tazobactam (tazocin ®) scheme,
compared with the classical scheme, evaluate its efficacy, safety index.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital